Associations between single nucleotide polymorphisms in the FAS pathway and acute kidney injury

Table 4 Top 15 Fas/Fas ligand pathway polymorphisms in the Fluid and Catheter Treatment Trial associated with acute kidney injury (AKI) (stage 2–3 vs. stage 0) in Caucasians (stage 1 excluded)

Gene	SNP	OR (95 % CI)^a	P value	FDR	MAF
NFKBIA	rs1050851	4.00(2.10–7.62)	1.05 × 10⁻⁵	<0.003	0.18
NFKBIA	rs2233417	4.03(2.09–7.77)	1.88 × 10⁻⁵	<0.003	0.15
BAX	rs4645878	0.12 (0.02–0.90)	0.004	0.41	0.12
TIRAP	rs3802814	2.45 (1.28–4.72)	0.008	0.55	0.14
BCL2L1	rs6058381	0.13 (0.02–1.02)	0.008	0.48	0.09
BAX^b	rs2387583	0.20 (0.05–0.89)	0.009	0.42	0.13
NFKBIA	rs7157810	2.19 (1.22–3.94)	0.009	0.38	0.18
BAX	rs1010103	0.21 (0.05–0.92)	0.01	0.38	0.13
LY96	rs16938758	2.22 (1.21–4.09)	0.01	0.34	0.17
ALS2CR1	rs17468277	2.36 (1.15–4.88)	0.02	0.67	0.10
DAXX	rs2239839	2.05 (1.10–3.82)	0.02	0.61	0.26
CASP8	rs1045485	2.32 (1.12–4.78)	0.03	0.64	0.11
CASP9	rs1820204	1.84 (1.04–3.27)	0.03	0.770	0.47
BCL2	rs1542578	0.55 (0.31–0.97)	0.04	0.72	0.49
TIRAP	rs8177343	1.98 (1.03–3.79)	0.04	0.79	0.16

^aRisk of AKI (stage 1 or above) with each additional copy of the minor allele. ^bAlso nominally associated with stage 2–3 AKI in African-Americans (p <0.05). SNP single nucleotide polymorphism, OR odds ratio, FDR false discovery rate, MAF minor allele frequency

ISSN: 1364-8535